现在所在位置:首页>科技成果>科研论文>
Nat Commun:Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus

Nat Commun. 2015 Mar 30;6:6714. doi: 10.1038/ncomms7714.

Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus.
Chen Z1, Wang J1, Bao L2, Guo L1, Zhang W1, Xue Y1, Zhou H1, Xiao Y1, Wang J1, Wu F3, Deng Y4, Qin C2, Jin Q1.
Author information
1MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
2Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical Collage (PUMC), Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Beijing, China.
3Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
4Beijing Municipal Center for Disease Control and Prevention, Beijing, China.

Abstract

The recently identified avian-originated influenza H7N9 virus causes severe pulmonary disease and may lead to death in humans. Currently, treatment options for the prevention and control of fatal H7N9 infections in humans remain limited. Here we characterize two human monoclonal antibodies (HuMAbs), HNIgGA6 and HNIgGB5, by screening a Fab antibody phage library derived from patients who recovered from H7N9 infection. Both antibodies exhibit high neutralizing activity against H7N9 virus in cells. Two amino acids in the receptor-binding site, 186V and 226L, are crucial for the binding of these two HuMAbs to viral haemagglutinin antigens. Prophylaxis with HNIgGA6 and HNIgGB5 confers significant immunity against H7N9 virus in a mouse model and significantly reduces the pulmonary virus titre. When administered post infection, therapeutic doses of the HuMAbs also provide robust protection against lethality. These antibodies might represent a potential alternative or adjunct to H7N9 pandemic interventions.

全文下载